A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
Michael R. McClung(Bone Health and Osteoporosis Foundation), Pierre D. Delmas(Inserm), José Zanchetta(Universidad del Salvador), Rachelle Eusebio(Procter & Gamble (United States)), Robert R. Recker(Creighton University), Witold Tłustochowicz(Wojskowy Instytut Medycyny Lotniczej), Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wojciech P. Olszynski(University of Saskatchewan), Claude-Laurent Benhamou(Inserm), Ana Balske(Providence Center)
Cited by 10
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k